Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116798 | 0.89 | PTPN1 (0.42) | PTPN1PTPN2 | |
| SCHEMBL5123269 | 0.86 | PTPN1 (0.43) | PTPN1PTK2PTPN2FYNTSHR | |
| SCHEMBL5128482 | 0.83 | ALDH1A1 (0.32) | PTPN1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5123264 | 0.83 | CA12 (0.39) | PTPN1TSHR | |
| SCHEMBL5117806 | 0.82 | ALOX5 (0.42) | — | |
| SCHEMBL5116472 | 0.75 | ALOX5 (0.42) | — | |
| SCHEMBL5127766 | 0.74 | CA12 (0.39) | PTPN1TSHR | |
| SCHEMBL5127605 | 0.74 | PTPN1 (0.46) | PTPN1PTPN2 | |
| SCHEMBL5130066 | 0.73 | PTPN1 (0.38) | PTPN1PTPN2 | |
| SCHEMBL5123712 | 0.73 | CA12 (0.39) | PTPN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004325-A1 | PTP1B inhibitors | WYETH (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004325-A1 | PTP1B inhibitors | PTPA, PTPRJ, PTPRR | PTPN1 18/4885PTK2 540/4885PTPN2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.